Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly.

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported less-than ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes ...

Philip Bakleski (Phiality) has published a paper on GitHub about a method called 'Chain of Recursive Thoughts (CoRT),' which allows an AI to think more deeply by repeatedly asking itself questions.

If history repeats, as Karl Marx said, first as tragedy and then as farce, what happens if the repetitions keep coming, while those who forget the past (or actively erase it) are doomed to repeat it?

The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals ...

Recursion Pharma’s May update is the primary near-term driver of its stock. The company ended 2024 with $60M in cash, providing runway till 2027. Get access to the leaderboards pointing to ...

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other firms that hit hard in Thursday’s trading. Shares of 10 companies were ...